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Biallelic BRCA2 Mutations Shape the Somatic
Mutational Landscape of Aggressive Prostate Tumors
Brennan Decker,1,2 Danielle M. Karyadi,1 Brian W. Davis,1 Eric Karlins,1 Lori S. Tillmans,3
Janet L. Stanford,4 Stephen N. Thibodeau,3 and Elaine A. Ostrander1,*
To identify clinically important molecular subtypes of prostate cancer (PCa), we characterized the somatic landscape of aggressive
tumors via deep, whole-genome sequencing. In our discovery set of ten tumor/normal subject pairs with Gleason scores of 8–10 at diag-
nosis, coordinated analysis of germline and somatic variants, including single-nucleotide variants, indels, and structural variants, re-
vealed biallelic BRCA2 disruptions in a subset of samples. Compared to the other samples, the PCa BRCA2-deficient tumors exhibited
a complex and highly specific mutation signature, featuring a 2.88-fold increased somatic mutation rate, depletion of context-specific
C>T substitutions, and an enrichment for deletions, especially those longer than 10 bp.We next performed a BRCA2 deficiency-targeted
reanalysis of 150 metastatic PCa tumors, and each of the 18 BRCA2-mutated samples recapitulated the BRCA2 deficiency-associated mu-
tation signature, underscoring the potent influence of these lesions on somatic mutagenesis and tumor evolution. Among all 21 indi-
viduals with BRCA2-deficient tumors, only about half carried deleterious germline alleles. Importantly, the somatic mutation signature
in tumors with one germline and one somatic risk allele was indistinguishable from those with purely somatic mutations. Our observa-
tions clearly demonstrate that BRCA2-disrupted tumors represent a unique and clinically relevant molecular subtype of aggressive PCa,
highlighting both the promise and utility of this mutation signature as a prognostic and treatment-selection biomarker. Further, any test
designed to leverage BRCA2 status as a biomarker for PCamust consider both germline and somaticmutations and all types of deleterious
mutations.Introduction
Prostate cancer (PCa [MIM: 176807]) is the most common
non-cutaneous malignancy and second leading cause of
cancer deaths in American men, with approximately
220,800 diagnoses and 27,540 deaths projected in 2015.1
The 5-year survival for local disease is nearly 100%,
compared to only 28% for metastatic disease.2 This
outcome disparity frames themajor clinical challenge asso-
ciated with PCa: distinguishing those men who are likely
to get metastatic disease, whichmight be prevented by spe-
cific and early therapy, while minimizing the iatrogenic
morbidity associated with overtreatment of indolent dis-
ease. Though clinical measures including Gleason score
and quantification of prostate-specific antigen have prog-
nostic utility, the current risk stratification framework mis-
classifies a critical subset of tumors. Consequently, a great
deal of PCa research is focused on finding molecular and
genetic biomarkers that facilitate early and accurate identi-
fication of men with potentially high-risk tumors.
Whole-exome sequencing (WES) and whole-genome
sequencing (WGS) studies have provided a window into
the biology that drives oncogenesis and progression of
PCa tumors by enabling unbiased exploration of somatic
mutations in prostate tumors that span the spectrum of
aggressiveness disease.3–10 WES-based studies of tumors
have highlighted genes that are recurrently mutated,3,4,6,8
andWGS efforts defined a prominent role for structural re-
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nucleotide variants (sSNVs), indels, and structural variants
(SVs) is important for understanding the repertoire of
genomic aberrations that contribute to PCa. This hypothe-
sis was confirmed by a recent study that reported different
variant types combining to knock out both copies of recur-
rently mutated genes inmetastatic PCa tumors.8 In spite of
these findings, considerable work remains to understand
the relationship between somatic genomic alterations and
tumor aggressiveness.
Our initial approach used deep WGS in a discovery set
of ten high-Gleason-grade prostate tumor/normal subject
pairs from the Mayo Clinic to search for drivers of PCa
aggressiveness. Via combined analysis of germline and
somatic SNVs, indels, and SVs, we uncovered biallelic
loss of BRCA2 (MIM: 600185) in three of the ten sequenced
tumors. Although BRCA2 mutations or larger chromo-
some13 deletions have been reported to affect a small per-
centage of PCa tumors,3,8–10 the effect of these mutations
on the PCa tumor genome has not been elucidated. As
such, although the clinical importance of BRCA2 defi-
ciency might be inferred, we sought to explicitly define
the genome-wide consequences of biallelic BRCA2 loss in
PCa tumors and thereby solidify the clinical importance
of BRCA2 defects in PCa.
Breast, ovarian, pancreatic, and gastric tumors with germ-
line and/or somaticBRCA2defects have adistinctive somatic
mutation profile that results from the inability of cells
to repair double-strand DNA breaks via the high-fidelityethesda, MD 20892, USA; 2Centre for Cancer Genetic Epidemiology, Depart-
CB1 8RN, UK; 3Department of Laboratory Medicine and Pathology, Mayo
utchinson Cancer Research Center, Seattle, WA 98109, USA
016
Table 1. The Whole Genomes of Nine Highly Aggressive, Treatment-Naive Primary Prostate Tumors and One Nodal Metastasis Were
Sequenced
Sample Gleason Score Age at Diagnosis PSA at Diagnosis (ng/dL) Germline Cov. Tumor Cov. Est. Purity (%)a Est. Ploidy
MC-1T 9 60 5.1 52.1 101.5 49 2.14
MC-2T 8 68 7.1 48.1 87.5 51 1.96
MC-3T 9 54 17.5 48.4 98.5 56 2.1
MC-4T 9 77 17.7 50.5 97.7 50 2.15
MC-5T 9 62 4.4 52.2 100.3 79 2.08
MC-6T 10 76 15.2 46.9 103.5 50 2.19
MC-7T 9 56 7.93 45.5 96.2 62 2.22
MC-8T 9 66 11.14 48.2 82.5 59 2.25
MC-9T 8 54 7.68 45.7 92.2 75 1.96
MC-10M 7b 63 22.3 45.1 93.1 75 2.51
MEAN – 63.6 11.6 48.3 95.3 60.6 2.2
Additional clinical information and sequencing metrics can be found in Tables S1 and S2. Purity and ploidy were estimated with Patchwork.24
aAll tumors were macrodissected to target at least 70% Gleason grade 4þ cytoarchitecture, and the purity estimate reported here is the actual purity calculated
from sequencing data.
bFor MC-10M, the Gleason score refers to the primary tumor, while the sequenced DNA was isolated from a nodal metastasis.homologous recombination (HR) pathway.11–16 These tu-
mors exhibited an elevatedmutation rate and also had char-
acteristic substitution and indel patterns, evidence that
BRCA2 loss produces a powerful, pervasive effect on the can-
cer genome. We hypothesized that if BRCA2 mutations are
crucial drivers of PCa tumor evolution, then samples with
biallelic loss of the gene should exhibit a somatic mutation
profile that mirrors the BRCA2 deficiency from other tumor
types. Our WGS characterization of the three discovery
set tumors from the Mayo Clinic, as well as our BRCA2
deficiency-targeted reanalysis of 150 metastatic tumors,
including 18 with BRCA2 defects, supports this hypothesis.
Furthermore, we show that PCa tumors with purely somatic
disruption of BRCA2 not only have the same mutation
signature, but occur at the same frequency as tumors with
germline plus somaticmutations. Thus, our analyses suggest
that tumor BRCA2 status and the associated somatic muta-
tion signature represent a clinically relevant molecular
biomarker in PCa.Material and Methods
Sequencing, Variant Calling, and Analysis of WGS
Samples
The discovery set of ten Mayo Clinic tumor samples was selected
for sequencing based on high Gleason score and availability of
both peripheral blood DNA and fresh frozen prostatectomy sam-
ples. Subjects had a mean age at diagnosis of 63.6 years (range
54–77 years) and all were of European descent (Tables 1 and S1).
The Mayo Clinic IRB approved the study design, and consent
was obtained at the time of sample collection. For each frozen
tumor sample, an initial H&E-stained slide was reviewed by a
pathologist. An area was marked that contained more than 70%
tumor cells and a Gleason score greater or equal to 8. The block
was then serially cut into six 10-mm thick sections immediately af-The Amter the marked H&E slide. With the H&E-stained slide as a guide,
the marked area was macro-dissected from unstained sections on
dry ice and placed into a tube for DNA extraction. The DNA was
extracted via the Puregene Tissue Kit (QIAGEN) and the corre-
sponding genomic DNA was extracted from white blood cells via
the AutoGen FLEX STAR system (AutoGen). Sequencing libraries
were prepared with the Illumina TruSeq v2 kit (Illumina) and
then sequenced with the Illumina HiSeq 2000 Genome Analyzer
platform to generate 100-base paired-end reads, according to man-
ufacturer’s protocols. Tumor DNA was sequenced to a genome-
wide average depth of 95.33 and average germline coverage was
48.33 (Tables 1 and S2).
After sequencing data were generated, both the discovery set
samples and the WGS reads from the 50 tumors spanning the
aggressiveness spectrum described by Baca et al.5 were processed
via an identical analysis pipeline. Reads were aligned to the
NCBI GRCh37 human reference genome with BWA v.0.7.2,17
PCR duplicates were marked with Picard v.1.87, and GATK v.3.2
was used for local realignment around indels and base quality
score recalibration.18
We performed SNVand indel discovery, genotyping, and variant
quality score recalibration in all tumorandgermline samples simul-
taneously, according to the GATK HaplotypeCaller v.3.2 best prac-
tices recommendations.19 Indels that were multiallelic or found
in any germline sample were subtracted from each tumor, and
remaining indels with VQSLOD > 0.8209 (Tranche 98.0) were
retained for somatic analyses. Indels were classified as either dele-
tions or insertions, and the length of each variant was calculated
(Table S3).WeusedMuTect to compare tumor andnormal bamfiles
for first pass sSNVdetection,20 then removedanyvariants thatwere
(1) present in the HaplotypeCaller genotypes from germline sam-
ples, (2) present in dbSNP but not the COSMIC database, or (3)
powered at less than 0.9 for either the somatic or germline sample.
Somatic substitution mutational signatures were created with the
reference allele, alternate allele, and adjacent bases in the reference,
as previously described.12 The predicted effect of indels and
sSNVswere calculatedwith theVariant Effect Predictor21 andanno-
tated with further functional predictions with CADD v.1.2.22erican Journal of Human Genetics 98, 818–829, May 5, 2016 819
Somatic and germline BRCA2 indels were confirmed with Sanger
sequencing. For MC-6T, Haploview was used to evaluate linkage
disequilibrium between the germline indel and variants inside
the deleted region,23 and phased haplotypes from the 1000
Genomes Project was used to project which chromosomes were
affected by the rare germline indel and the somatic deletion.
Genomic architecture analysis was conducted with the R pack-
age Patchwork, which leverages normalized coverage and allelic
imbalance to detect clonal and subclonal changes in copy num-
ber in 10-kb windows across the genome.24 Patchwork plots for
MC-1T were excluded from further analyses due to high vari-
ability in normalized coverage between the tumor and germline
samples. Local somatic allelic imbalance was detected using plots
of SNV sites that (1) were genotyped as heterozygous in the
germline sample, (2) were present in dbSNP v.137 and therefore
had a higher likelihood of being true germline variant positions,
and (3) had a reference allele fraction in the normal sample be-
tween 0.45 and 0.55 (to remove positions with systematic allelic
bias). Patchwork was also used to estimate tumor purity and
ploidy.
We used DELLY v.0.5.5 to identify deletions (DEL), tandem du-
plications (DUP), inversions (INV), and translocations (TRA) in
all tumor and normal genomes.25 Raw somatic DELLY calls
were filtered to remove probable false positives by excluding
SVs that had a size <1 kb or where either SV breakpoint fell
within 100 kb from the start or end of a chromosome. Candidate
SVs were merged into a single event when both breakpoints
were 5200 bp for INV, DEL, DUP and 5500 bp for TRA. SVs
were also filtered if split-read support (SR) < 1 and paired-end
read support (PE) < 5 or PE < 1 and SR < 5. As with the SNVs
and indels, we employed a panel of normals approach to remove
germline SVs or systematic errors. We excluded any variant of
the same subtype that was present in any germline genome
within the same margin of errors used for merging. A catalog
of high-confidence sSNVs, indels, and SVs that are predicted to
disrupt the coding region of genes and were found in the dis-
covery set and the tumors unselected for aggressiveness are in
Table S4.BRCA2 Deficiency-Targeted Reanalysis of Metastatic
WES Tumors
We performed a BRCA2 deficiency-targeted reevaluation of all var-
iants documented in 150 metastatic PCa samples from Table S3 of
the publication by Robinson et al.8 to determine whether the HR-
deficient mutation signature was also present in this dataset,
which included 18 samples with biallelic BRCA2 mutations, one
sample with biallelic hits in BRCA1 (MIM: 113705), and three sam-
ples with biallelic aberrations in DNA mismatch repair genes. The
trinucleotide sequence context of each substitution was extracted
from the hg19 reference sequence using a bespoke python script,
and mutation signatures were created for each tumor, as above.
Deletion-to-insertion ratios and indel length distributions were
tabulated for each tumor (Table S3). All variants were annotated
with CADD, and raw scores were used to compare groups of sam-
ples, as recommended by the authors of that program.22 Samples
with mutations in BRCA1 or mismatch repair (MMR) genes were
excluded from all comparisons of mutation rates or characteris-
tics. Instead, the 18 BRCA2-disrupted tumors were compared to
the 128 samples without BRCA1, BRCA2, or MMR defects. The
single BRCA1-mutated tumor, as well as the three MMR-deficient
samples, were evaluated independently.820 The American Journal of Human Genetics 98, 818–829, May 5, 2Statistical Methods
Hierarchical clustering was performed on the substitution signa-
tures with the complete linkage method using R hclust package,
which supported grouping the discovery set tumors by BRCA2 sta-
tus for downstream analysis. For all comparisons of tumor sub-
groups, observed values were log transformed and p values were
fitted with a logistic regression model using the R glm package.26
Two-by-two tables were evaluated for significant associations
using Fisher’s exact test.
Pathways Analysis
Pathways analysis for the metastatic tumors was performed on
a gene list comprising truncating sSNVs and indels plus genes
affected by fusions using the online portal for the Gene Set Enrich-
ment Analysis (GSEA) program.27 For each tumor, we tested for
enrichment of mutated genes in canonical pathways using the
list of genes with truncating mutations, in-frame indels, fusion
genes, or missense changes that had a PHRED-scaled CADD
score22 >20. BRCA2 mutations were masked to avoid bias related
to the fact that these aberrations were present in all tumors in
the HR-deficient group. All pathways with FDR q value < 0.05
were retained. For each pathway, we then compared the number
of BRCA2-mutated tumors enriched for that pathway versus the
number of tumors without BRCA1, BRCA2, or MMR mutations.Results
To access the genomic landscape of aggressive, treatment-
naive prostate tumors, we initially performed deep, paired-
end tumor/normal whole-genome sequencing of nine fresh
frozen prostatectomy samples with Gleason scores of 8–10
(MC1-9T),plus onenodalmetastasis froma tenth individual
(MC-10M), all from theMayoClinic (Tables 1 and S1).Mean
tumor coverage was 95.33 and mean normal sample
coverage was 48.33 (Tables 1 and S2). In each matched
tumor and normal sample, we genotyped SNVs, indels,
and SVs, and then used quality filters and a panel of normal
samples to remove germline variants and systematic errors.
Inspection of somatic mutation counts revealed that
three tumors (MC-6T, MC-8T, and MC-10M) had an
elevated somaticmutation rate compared to the other sam-
ples in this discovery set (Figure 1A). For all variant types
combined, these samples had a 2.88-fold greater muta-
tion rate compared to the other seven aggressive prostate
tumors, with means of 4.735 0.55 per Mb versus 1.645
0.27 per Mb, respectively (Figure 1A, p value ¼ 4.74 3
104). Although this elevatedmutation rate was significant
for both somatic SNVs and small indels (Figure S1, p value¼
4.743 104 for both), SVs did not contribute to this signal,
either in aggregate (1.03-fold enrichment, p value¼ 0.818)
or among any of the assessed SV subtypes, including
largedeletions, translocations, duplications, and inversions
(somatic mutation metrics for all samples are in Table S3).
There were six genes that harbored somatic mutations
in at least three tumors: ERG (MIM: 165080), TMPRSS2
(MIM: 602060), BRCA2, KMT2C (MIM: 606833), TFDP1
(MIM: 189902), and VPS13B (MIM: 607817) (Figure 1A).
The majority of the variants in recurrently mutated genes016
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Figure 1. Inherited or Acquired Muta-
tions Combine to Cause Biallelic Loss of
BRCA2 in Three of the Ten Discovery Set
PCa Tumors
(A) Three samples had a significantly
elevated mutation rate compared to the
other seven tumors. Six genes harbored so-
matic mutations in three or more tumors.
For this purpose, SVs were counted only
when the breakpoints were within a gene
and the orientation or integrity of at least
one exon was interrupted. BRCA2 was the
only gene that was mutated in all three
tumors with an elevated mutation rate.
(B) Truncating indels, all confirmed via
Sanger sequencing, were detected in each
of the affected tumors. Nucleotide and pro-
tein changes are reported with respect to
RefSeq accession numbers GenBank: NM_
000059.3 and NP_000050.2, respectively.
(C) All three tumors also have copy loss at
the locus. The blue line indicates somatic
copy number, with SV breakpoints marked
by red arrows. Black dots represent allelic
imbalance for heterozygous dbSNP 137
SNVs that had variant allele fraction be-
tween 45% and 55% in the normal DNA.
The redbox indicates thepositionofBRCA2.were SVs, accounting for 14 of 19 mutations overall. In
addition, the aggressive tumor discovery set had two sam-
ples withmutations in other genes that have been found to
be recurrently mutated in PCa, including FOXA1 (MIM:
602294), PARK2 (MIM: 602544), PTEN (MIM: 601728),
SPOP (MIM: 602650), and TP53 (MIM: 191170) (Table S4).
Discovery Set Samples with Biallelic BRCA2
Mutations Had a Distinctive Somatic Mutation
Landscape
We then investigated whether the tumors with an elevated
total mutation rate had mutations in the same gene or
pathway and found that all three tumors had biallelic
disruption of BRCA2 (Figure 1). One tumor (MC-6T) had
one germline and one somatic mutation, whereas the
other two (MC-8T and MC-10M) each had two deleterious
somatic mutations. In all three, one SV and one indel
combined to abolish both copies of BRCA2 (Figure 1). In
two samples (MC-8T and the metastatic lesion MC-10M)
we observed that complex structural rearrangements
caused a single copy loss of BRCA2, and somatic frameshift
deletions in exon 11 disrupted the other allele (Figures
1B and 1C). In MC-10M, follow-up Sanger sequencingThe American Journal of Humashowed that the somatic indel was
present in the primary tumor, in addi-
tion to the metastatic lesion. MC-6T
had a somatic 39.1-Mb deletion with
a breakpoint between exons 21 and
22 that excised the last six exons of
the gene, and also a pathogenic germ-
line frameshift deletion in exon 14
(Figures 1B and 1C). These two trun-cating variants probably affect both chromosomes, as
determined by 1000 Genomes-based phasing of a common
SNP on the same sequencing reads as the germline indel,
and hemizygous SNPs after the somatic deletion break-
point (Figure S2 and Table S5). Purity-corrected allelic ra-
tios of the frameshift indels, together with Patchwork24
analysis of both allelic imbalance and normalized tumor
sequencing depth for SVs (Figure S3), indicated that bial-
lelic BRCA2 loss was clonal in all three tumors.
BRCA2-disrupted tumors not only harbored 2.91-fold
more sSNVs (Figures 1A and S1A) but also exhibited a
distinct somatic substitution profile. These three samples
had a significantly lower transition to transversion ratio
than the other tumors (p value ¼ 4.74 3 104; Figure S1B).
Indeed, the seven BRCA2-intact tumors were dominated
by C>T transitions, which accounted for an average of
35.6% of all substitutions in these samples (Figures 2A and
S4). Placed into their trinucleotide sequence context, these
C>T substitutions were especially common in NpCpG trip-
lets (Figure 2B). Tumors with biallelic BRCA2mutations, in
contrast, showed closer to equal representation of each
substitution, with C>T mutations amounting to only an
average of 24.5% of sSNVs (Figures 2A and S4).Within theirn Genetics 98, 818–829, May 5, 2016 821
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Figure 2. In the BRCA2-Deficient Tumors,
both sSNVs and Indels Had Distinctive
Characteristics
(A) Tumors without biallelic BRCA2 muta-
tions had nearly twice as many C>T sSNVs
thananyother substitution.C>T transitions
represented a significantly smaller propor-
tion of the substitutions in BRCA2-deficient
tumors (Student’s t test p value¼ 0.0015).
(B) This signal is driven by a predilection
in BRCA2-intact tumors for C>T substitu-
tions within specific trinucleotide sequence
contexts, particularly ACG, CCG, CCG, or
TCT, where ‘‘C’’ is the substituted base.
(C) This pattern was absent in the three
BRCA2-mutated tumors, which instead had
closer toequal likelihoodofeach substitution
and each trinucleotide sequence context.
(D) HR-competent tumors acquired somatic
insertions and deletions at roughly the
same rate, and these were overwhelmingly
short, with 63.1% spanning a single base.
(E) In the setting of BRCA2 deficiency, dele-
tions were more common than insertions
and long deletions were common, account-
ing for more than 30% of all somatic indels
in these tumors.
For all panels with error bars, these repre-
sent the standard deviation from the
mean of all samples in that category.trinucleotide sequence context, this lack of a single domi-
nant substitution was further manifest as a flattened muta-
tion signature, without the characteristic context-specific
transitions seen in the other tumors (Figure 2C).
Biallelic loss of BRCA2was also associated with a 3.13-fold
increase inthesomatic indel rate (Figures1AandS1C;pvalue
¼ 4.74 3 104), and, like the sSNVs, the characteristics of
these mutations were divergent from the other tumors.
This elevated somatic indel rate was driven by both inser-
tions (p value ¼ 2.49 3 103) and deletions (p value ¼
4.743 104), but the magnitude of enrichment was greater
for deletions (4.15-fold versus 1.96-fold, Table S3). Tumors
without BRCA2mutations acquired deletions and insertions
atnearly the same rate, leading to amean ratio of 1.1830.22
(Figures 2D and S1D). In contrast, samples with biallelic
BRCA2 loss hadmore than twice as many deletions as inser-
tions, with amean ratio of 2.435 0.18 (Figures 2E and S1D,
p value ¼ 4.74 3 104). In addition, loss of BRCA2 yielded
longer deletions (Figures 2D and 2E). On average, 28.2% of822 The American Journal of Human Genetics 98, 818–829, May 5, 2016deletions spanned ten or more bases in
these tumors, compared to only 10.8%
in the remaining samples (Figures 2D,
2E, and S1E, p value ¼ 4.743 104).
BRCA2-Deficient Tumors Were
Outliers Compared to PCa Samples
Spanning the Aggressiveness
Spectrum
We next sought to place BRCA2 disrup-
tion-associated somatic mutation rateand patterns into the context of other prostate tumors
from across the clinical aggressiveness spectrum. Using the
same pipeline established for the discovery set of tumors,
we regenotyped somatic variants in theWGS of 50 prostate
tumors, which weremade publically available from a recent
publication by Baca et al.5 These tumors were treatment
naiveandwerenot specifically selected foraggressivedisease
with 35 Gleason % 7, 11 Gleason 8–10, and 4 tumors
without a published Gleason score. The average WGS
sequencing depthwas 613 for tumors and 343 formatched
normal. Among these 50 additional tumors, none harbored
monoallelic or biallelic BRCA2mutations. Strikingly, when
considered within the context of the discovery set tumors
plus those that were unselected for aggressiveness, the three
discovery set samples with biallelic BRCA2 mutations
remained clear outliers by all measures that defined the
distinctive BRCA2-deficient molecular subtype. In compari-
sonwith all tumors fromboth datasets, as well as only those
with Gleason score of eight or greater, the BRCA2-deficient
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Figure 3. The Somatic Mutation Patterns
Found in the Three Discovery Set Tumors
with Biallelic BRCA2 Loss WereMaintained
when Compared to 50 Additional PCa
Tumor WGS5 that Spanned the Range of
Clinical Aggressiveness
Samples are color coded by BRCA2 status
and study of origin, as indicated in the
legend. As observed in the discovery
set alone, biallelicBRCA2 losswas associated
with (A) an elevated sSNVmutation rate, (B)
a depressed transition-transversion ratio,
and (C) enrichment for somatic deletions.
Strikingly, the threeBRCA2-deficient tumors
were the only samples with elevations of
both the deletion to insertion ratio and the
fraction of deletions exceeding 10 bp (D).tumors had the three highest sSNV rates (Figure 3A, p value
¼ 1.063106) andalso the three lowest transition-transver-
sion ratios (Figure 3B, p value¼ 1.063 106). The divergent
BRCA2-disrupted indel trends also persisted when placed
into the context of all 60 tumors. The three BRCA2 muta-
tion-carrying tumors had a significantly elevated deletion
mutation rate (Figure3C, pvalue¼1.173105), in addition
to being the only samples with a preponderance of both de-
letions over insertions plus enrichment for long deletions
(Figure 3D). It is unlikely that systematic differences be-
tween the studies played any role in the persistence of these
BRCA2mutation-associated patterns, because the seven dis-
covery set tumors without BRCA2 disruptions were largely
indistinguishable from the samples that were unselected
for aggressiveness (Figure 3, p values ¼ 1.06 3 106 for
both observations).
Metastatic Tumors with Biallelic BRCA2 Mutations
Recapitulated the Somatic Mutation Profile
We next tested the reproducibility of the BRCA2-muta-
tion-associated somatic genomic signature by performing
a BRCA2 deficiency-targeted reanalysis of 150 metastatic
tumors that were recently characterized by Robinson et al.8
Although the other two datasets contained metastatic tu-
mors, the Robinson et al. dataset is subsequently referred to
as ‘‘metastatic tumors’’ because of the selection criteria used
for data collection. In deep WES and copy-number assess-
ment of primary tumors and metastases from 18 metastatic
PCa cases, 12.0% had biallelic mutations in BRCA2 and
one tumor (0.7%) had biallelic loss of BRCA1. As in the
BRCA2-mutated tumors from the discovery set, complex
combinations of both germline and somatic lesions contrib-The American Journal of Humauted to the loss ofBRCA2: nine samples
(6.0%) had both germline and somatic
BRCA2 mutations, and nine tumors
(6.0%) had purely somatic SNVs, in-
dels, and SVs that combined to yield
biallelic loss of BRCA2 (Table S6). The
single samplewith biallelicBRCA1mu-
tations also had one germline and one
somatic mutation.Like the BRCA2-mutated discovery set samples, we found
that the metastatic tumors with BRCA2 mutations had
a significantly elevated sSNV mutation rate (Figure 4A,
p value¼ 1.243 105; somaticmutationmetrics for all sam-
ples are inTableS3).Within the18BRCA2-deficient samples,
wedidnotdetecta significantdifference inmutationratebe-
tween thosewith purely somatic biallelicmutations versus a
combination of germline and somatic variants (Figure 4A,
p value ¼ 0.469). The single tumor with biallelic loss of
BRCA1 had a similar sSNV rate to the BRCA2-mutated
samples.
Although the BRCA2-disrupted tumors had an elevated
mutation rate compared to the average metastatic sample,
it was notable that four tumors exhibited an even higher
sSNVmutation rate. Three of thesehadbiallelic somatic dis-
ruptions ofMLH1 (MIM: 120436) orMSH2 (MIM: 609309),
mismatch repair (MMR) genes that whenmutated produce
a classic hypermutator phenotype.28 Compared to these
hypermutated MMR-deficient samples, the sSNVmutation
rate inBRCA2-mutated tumorswas significantly lower,with
means of 28.72 5 5.82 per Mb and 5.05 5 1.70 per Mb,
respectively (Figure 4A, p value ¼ 3.32 3 105).
Upon examination of the somatic substitutions and their
trinucleotide sequence contexts, the metastatic samples
mirrored the overarching trends seen in their discovery
set counterparts. The 128 tumors without BRCA1, BRCA2,
or MMR mutations exhibited even more dramatic enrich-
ment for C>T substitutions than was observed in the seven
discovery set non-BRCA2 mutated tumors, accounting for
51.9% of all sSNVs, and these were especially common
within the triplets ACG, CCG, and GCG (Figure 4B). In
contrast, the 18 samples with biallelic BRCA2 mutationsn Genetics 98, 818–829, May 5, 2016 823
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Figure 4. Nearly Identical Somatic Muta-
tion Signatures Were Detected in Our
BRCA2 Deficiency-Targeted Reanalysis of
150 Metastatic Prostate Tumors,8 18 with
Biallelic Loss of BRCA2, 1 with Biallelic
Mutations in BRCA1, and 3 with Biallelic
MMR Defects
(A) Germline and somatic defects shared a
statistically indistinguishable propensity
to cause a modest increase in the sSNV
mutation rate.
(B) C>T substitutions were most frequent
in metastatic HR-competent PCa, exhibit-
ing even greater enrichment than observed
in the discovery set tumors.
(C) In contrast, C>T transitions were
not dramatically overrepresented in the
BRCA2-deficient tumors.Much of the differ-
ence is derived from a paucity of substitu-
tions within the triplets ACG, CCG, and
GCG, which were characteristic in their
HR-intact counterparts.
(D) As seen in these tumors among sSNVs,
germline and somatic HR defects led to a
similar rise in the indel mutation rate.
(E) Samples with biallelic HR deficiency had
enrichment for both deletions over inser-
tions and long deletions, recapitulating the
trend observed in the discovery set tumors.
(F) The number of truncating indels was
partially determined by differences in the
somatic indel rate.
(G) BRCA2-mutated tumors had a higher
percentage of indels that were predicted
to truncate the encoded protein.
For all panels with error bars, these repre-
sent the standard deviation from the
mean of all samples in that category.had a significantly lower proportion of C>T substitutions,
accounting for just 37.4% (Figure 4C, p value ¼ 8.90 3
109). It was also notable that the tumor with biallelic
BRCA1 mutations (Figure S5A) exhibited a pattern that
closely resembled the BRCA2 deficiency-associated pattern
(Figure 4C). In contrast, the substitution context signature
in MMR-mutated tumors (Figure S5B) was indistinguish-
able from the other 128 samples (Figure 4B).
To determine whether these disparate C>T substitution
patterns influence the severity of the predicted effect on
the encoded protein, we annotated coding sSNVs with
CADD.22 Although BRCA2-deficient tumors had more
mutations at all CADD scores spanning the severity spec-
trum (Figure S6A), we observed no enrichment of highly
damaging mutations after adjusting for the mutation rate
(Figure S6B).
The indels identified in the BRCA2-disrupted metastatic
tumors also recapitulated themolecular signature observed
in the discovery set BRCA2-mutated tumors. In this data-
set, small deletions occurred at a significantly higher rate824 The American Journal of Human Genetics 98, 818–829, May 5, 2016in BRCA2-mutated samples than in
the BRCA1-, BRCA2-, and MMR-intact
tumors (Figure 4D, p value ¼ 8.38 3
108). Similar to the sSNVs, the sam-ple with biallelic BRCA1mutations had an indel mutation
rate that was consistent with the BRCA2-deficient tumors.
However, the BRCA2-mutated deletion rate was 26.3-fold
lower than in the three tumors with biallelic MMR lesions
(Figure 4D, p value ¼ 3.32 3 105). As we found for the
sSNV mutation rate, germline versus somatic origins of
BRCA2 defects did not significantly impact the somatic
deletion rate (Figure 4D, p value ¼ 0.531). Although there
were other tumors in the metastatic dataset that had either
an elevated deletion to insertion ratio or enrichment of
long deletions, the 18 BRCA2- and 1 BRCA1-mutated
tumors were the only samples that were outliers for both
characteristics (Figure 4E, p values ¼ 5.17 3 105 and <
2.2 3 106, respectively). The MMR-deficient tumors
were similar to one another, with an elevated deletion to
insertion ratio, but in contrast to the BRCA2-mutated sam-
ples, they were dominated by very short deletions.
To determine whether biallelic BRCA2 mutation status
influenced the predicted severity of indels, we compared
thenumber and rate of truncating indels inBRCA2-mutated
samples against the other tumors. The MMR- and BRCA2-
deficient metastatic tumors had a higher mean number of
truncating indels per sample than the other tumors
(Figure 4F). Although this was partially explained by the
elevatedmutation rate, further inspection of the 87 tumors
with at least 25 somatic indels revealed that the BRCA2-dis-
rupted tumors (p value ¼ 4.94 3 104), but not the MMR-
mutated samples, had a highermean proportion of variants
that were predicted to truncate the protein (Figure 4G).Pathways Analysis Highlights the Unique Evolution
of BRCA2-Mutated Tumors
In the metastatic tumor dataset, biallelic BRCA2 deficiency
was also associated with somatic mutation patterns in other
genes and pathways (Figure S7). Somatic PTEN mutations
were significantly underrepresented in BRCA2-mutated
tumors, as they were found in 44.5% of samples without
BRCA1, BRCA2, or MMR aberrations, but only 16.7% of
BRCA2-deficient samples (OR¼0.25, pvalue¼0.020).Other
recurrently mutated genes, APC (MIM: 611731), RB1 (MIM:
614041), and ATM (MIM: 607585), were also underrepre-
sented to a lesser extent in tumors without BRCA2 defects,
though the mutation rates did not meet the significance
threshold for these genes. Notably, ETS fusions, damaging
mutations to TP53, and AR (MIM: 313700) activating alter-
ations occurred at approximately the same rate, irrespective
of BRCA2 status (OR ¼ 0.71, 1.21, and 0.94, respectively).
PVT1 (MIM: 165140) (OR ¼ 8.86, p value ¼ 0.0085) and
OPHN1 (MIM: 300127) (OR ¼ 4.29, p value ¼ 0.036) muta-
tionsweremore common in the settingofBRCA2deficiency.
CHD1 (MIM: 602118) andKMT2Cwere also enriched in that
scenario, with ORs of 4.07 and 3.46, respectively.
Gene Set Enrichment Analysis27 for each sample did
not point to a single pathway driving difference beyond
BRCA2 mutations. However, tumors without BRCA1,
BRCA2, or MMR mutations were enriched for mutations
in canonical cancer driver pathways, including those
related to telomerase, TP53, RB, the cell cycle, and receptor
tyrosine kinases (Table S7). The KEGG pathway data-
base includes gene sets for multiple specific cancers, with
each set comprised of numerous, often overlapping onco-
genic drivers. These malignancy-specific pathways were
frequently implicated in samples without BRCA1, BRCA2,
or MMR deficiency, with 53/128 (41.4%) samples signifi-
cantly enriched for at least one KEGG cancer pathway,
compared to only 4/18 (22.2%) of BRCA2-mutated tumors
(OR ¼ 0.40, 95% CI ¼ 0.13–1.29, p value ¼ 0.128) (Table
S7). Focal adhesion, collagen formation, integrins, and
other cell-cell interaction networks were among the path-
ways that were more commonly enriched in BRCA2-
deficient samples (Table S7).Discussion
Our initial WGS of ten high-Gleason-grade tumors from
the Mayo Clinic revealed three samples with biallelicThe AmBRCA2 mutations, and these lesions were associated
with a highly specific somatic mutation signature. When
compared with the remaining samples, the BRCA2-defi-
cient tumors had a modest elevation in the somatic muta-
tion rate, a reduction in the rate of C>T substitutions, and
an increased rate of long somatic deletions. The somatic
SNV and indel mutation signature remained specific to
BRCA2-deficient tumors when compared to 50 additional
PCa tumors across the tumor aggressiveness spectrum.
Furthermore, the mutation pattern was reproducible in
our BRCA2 deficiency-targeted reanalysis of 150 metastatic
tumors, where 18 tumors with biallelic BRCA2 loss and
a single tumor with biallelic BRCA1 mutations mirrored
the somatic mutation signature observed in the discovery
set of BRCA2-mutated tumors, but diverged from the 128
tumors without loss of BRCA1, BRCA2, or MMR. The PCa
BRCA2-deficient mutation signature closely recapitulated
that found in breast, ovarian, pancreatic, and gastric can-
cers with mutations in BRCA1 or BRCA2.11–15 The pattern
was seen in all PCa samples with biallelic deleterious muta-
tions in the gene, which suggests that this mutational pro-
cess is a key driver of somatic mutations in affected tumors
and defines a clinically important molecular subtype of
PCa, irrespective of primary versus metastatic origins.
In a recent characterization of the trinucleotide substi-
tution profile across 36 cancer types, including 520 PCa
tumors, Alexandrov et al. found no prostate tumors with
the flattened mutation signature associated with BRCA2
deficiency,14 leading the authors to conclude that biallelic
HR mutations do not play an important role in PCa. How-
ever, we speculate that the 520 tumors were unselected for
disease aggressiveness, meaning only a small portion are
likely to be Gleason 8–10. Our study uncovered no HR
mutations in 39 non-aggressive tumors, but, in marked
contrast, biallelic loss and the associated mutation signa-
ture were present in 22/171 (12.9%) of aggressive and met-
astatic tumors in our study, suggesting that loss of BRCA2,
and possibly BRCA1, can play a crucial driver role in these
more clinically important tumors.
The observed mutation signature has been attributed
to the fact that HR-deficient cells cannot engage in double
strand break repair (DSBR) via the high-fidelity HR pathway,
but instead rely on error-prone strategies. Non-homologous
end joining (NHEJ) is one alternative repair mechanism that
leverages localmicrohomologynear the breakpoints to reap-
proximate the free DNA ends, followed by excision of the
overlapping microhomologous DNA.29 Because the length
of sequence identitydetermines thenumberofbasesdeleted,
DSBR via NHEJ probably explains why HR-deficient breast
and prostate tumors are dominated by long deletions.11
Though BRCA2 participates in many aspects of the DNA
damage response, reliance upon non-HR mechanisms for
DSBR might also contribute to the characteristic sSNV pro-
file, because alternative DSBR pathways induce mutations
via error-prone religation and gap-filling strategies.30 One
possibility is that themore equal representation of each sub-
stitution observed in HR-deficient samples probably reflectserican Journal of Human Genetics 98, 818–829, May 5, 2016 825
the fact that DSBR-related substitutions arise as a function of
their proximity to theDNAbreak, as opposed to the context-
specific substitution pattern found in other prostate tumors,
where the recurrent C>T transitions probably arose from
deamination of 5-methyl-cytosine at XpCpG trinucleotides.
In the PCa tumors analyzed in our study, HR-inactivat-
ing mutations exert a prominent effect on the mutational
landscape of prostate tumors, irrespective of whether
BRCA2 disruptions are inherited or purely somatic. There
was no apparent difference in the somatic mutation rates
(Figures 4A and 4D) or the nature of sSNVs and indels (Fig-
ures 4B, 4C, and 4E). The equivalent effects of germline
and somatic BRCA2 defects, paired with the highly similar
somatic mutation profiles of BRCA2-deficient tumors
from multiple tumor types, underscore the importance
of BRCA2 deficiency as a driver of somatic mutagenesis.
Thus, BRCA2 defects drive tumor evolution without regard
for the tissue type or origins of the mutation, and both
germline and somatic mutations appear to represent
important molecular biomarkers in PCa.
Our analysis supports previous observations that PCa in
subjects with germline BRCA2 risk alleles leads to a higher
rate of tumor aggressiveness, rapid progression, and poor
outcomes.31–33 Inherited BRCA2 alleles have also been
linked to a higher attributable risk in early-onset cases
and high-risk PCa families.34–36 Across all the samples as-
sessed in this study, 10/171 (5.8%) of subjects with aggres-
sive tumors had a germline BRCA2mutation. Our findings
indicate that truncating germline alleles are somewhat
more common in aggressive primary tumors with Gleason
scoresR8 (1/21 samples, 4.6%), and especially in metasta-
tic cases (9/150, 6.0%), compared to case subjects from
the general population.37,38 The fact that our study design
explicitly targeted tumors with aggressive clinical behavior
probably underlies our observed enrichment of germline
BRCA2-truncating alleles, given the increased risk of dis-
ease and aggressiveness associated with these mutations.
Furthermore, the stronger association between both PCa
risk and aggressiveness for BRCA2 compared to BRCA139
might explain our finding that BRCA2 was mutated more
often than BRCA1 in aggressive and metastatic PCa. Our
findings bolster targeted screening paradigms suggested
previously, including prostate cancer screening in carriers
of germline BRCA2 risk alleles40 as well as BRCA2 screening
for men diagnosed with aggressive or metastatic PCa,8
particularly when there is a family history of BRCA2-asso-
ciated malignancies.
Historically, oncogenesis in BRCA2-deficient cells has
largely been attributed to genomic rearrangements that
result from incompetent HR,41–43 a hypothesis supported
by observations that non-PCa tumors that are HR deficient
have more SVs than other tumors of the same type.15,44
In our analysis of PCa tumors, however, BRCA2-mutated
tumors did not have significantly more somatic SVs than
other tumors, perhaps due to the fact that PCa tumors
spanning the aggressiveness spectrum have a high SV
burden, which has been suggested as a key driver of pros-826 The American Journal of Human Genetics 98, 818–829, May 5, 2tate tumor evolution.5 Taken together, other genomic de-
rangements resulting from HR deficiency must contribute
to the more aggressive phenotype observed in BRCA2-dis-
rupted tumors. We found comparatively more sSNVs in tu-
mors with biallelic loss of BRCA2, but mutations resulting
from the distinctive HR-deficient substitution profile were
not more damaging than those that occur in the other 128
tumors (Figure S6). For indels, we observed both a higher
mutation rate in BRCA2-deficient samples and found that
those indels are more likely to cause predicted protein
truncations (Figures 4F and 4G), probably due to the fact
that the longer deletions in these tumors have a greater
chance of overlapping key genomic features. Based on
these findings, BRCA2 loss can contribute to tumor aggres-
siveness via an increased sSNV and indel mutation rate, as
well as the enhanced deleteriousness of the characteristic
long deletions, and not necessarily via the genomic insta-
bility that has been suggested as an oncogenic mechanism
in other tumors.
Somatic mutation patterns in BRCA2-mutated versus
other samples suggest that HR defects influence PCa tumor
evolution via different mechanisms than other cancers.
PTEN disruptions were common in metastatic samples
without BRCA2mutations (57/128, 44.5%), but not in sam-
pleswithbiallelicBRCA2 loss (3/18, 16.7%). This patterndif-
fers from HR-deficient breast and ovarian cancers, where
depletion of the PTEN protein is thought to play an impor-
tant role in tumor development.45–47 BRCA2-deficient
tumors also exhibit an aggressive clinical phenotype, in
spite of the fact that somatic PTEN loss has been suggested
as a key mediator of prostate tumor progression, especially
in conjunction with ETS fusions48 or suppression of the
JNK pathway.49 Although TP53 is thought to play a key
role in oncogenesis in breast and ovarian cancers with HR
defects,47,50 TP53 mutations were present in only 10/18
(55.6%) of the BRCA2-deficient samples in our study. Our
data indicate that PCa tumors with BRCA2 defects proceed
through oncogenesis and progression via different mecha-
nisms than other BRCA1- or BRCA2-associated malig-
nancies. Instead, PVT1, CDH1, or other genes that are
more frequentlymutated in samples with BRCA2 lossmight
influence evolution of PCa tumors with BRCA2 defects.
Larger studies of HR-deficient tumors would enable further
dissection of interactions between these genes in PCa.
Each example of biallelic BRCA2 loss in our study re-
sulted from a complex combination of variants, including
10/21 subjects with germline truncating alleles, so any
effort to identify clinically actionable variants in PCa
tumors must be sensitive to all variant types, germline
and somatic. In the 21 deficient tumors across the discov-
ery set and metastatic PCa studies, sSNVs represented just
7.1% (3/42) of the damaging alleles, whereas indels were
40.5% (17/42) of the total and SVs accounted for the re-
maining 52.4% (22/42). The overwhelming contribution
of difficult-to-detect variant types, paired with the fact
that tumor sequencing studies often do not systematically
assess germline alleles, might underlie the low reported016
frequency of BRCA2 mutations in earlier PCa sequencing
studies, including those that explicitly targeted more
aggressive tumors.3–10
Our analysis emphasizes that in order to leverage
BRCA2 status as a clinical biomarker in PCa, both germline
and somatic mutations, as well as all types of deleterious
mutations, must be considered. Given the mutation types
identified in our analysis, genotyping with multiple ap-
proaches would probably be necessary to achieve the high-
est possible sensitivity for clinically relevant mutations in
PCa. In the near term, economical detection of BRCA2mu-
tation status could be accomplished via exon sequencing
plus regional copy-number detection, though this approach
might miss balanced structural rearrangements, epigenetic
silencing, or disruptions elsewhere in the HR pathway. As
sequencing-based diagnostics are assimilated into clinical
testing protocols, incorporation of additional genome-
wide metrics like the mutational signature demonstrated
here (Figure 4) could yield more sensitive detection of HR
defects. Future studies are needed in order to determine
which approach most accurately identifies tumors with
HR defects. Indeed, the recent PCa clinical trial of a PARP
inhibitor showeddramatic response rates in tumorswithde-
fects spanning the HR pathway, concluding that targeted
sequencing is needed for all DNA-repair pathway genes.51
However, given the difficulty in identifying all possible
HR-disrupting somatic genomic aberrations, the molecular
signature might provide the most comprehensive way to
identify this specific subgroup of PCa tumors.
Notably, the three MMR-deficient tumors in the metasta-
tic tumor set also had a dramatic, distinguishing hyper-
mutation phenotype (Figure 4), which has been described
previously in prostate tumors and other cancers with MMR
inactivation.6,8,28,52 In contrast to BRCA2-deficient tumors,
the MMR-deficient tumors exhibited an elevated deletion-
to-insertion ratio with an enrichment of short deletions.
TheMMR tumors also had a consistentC to TsSNV substitu-
tion pattern that mirrored the overarching trend among
HR-competent prostate tumors in our study, as well as
MMR-deficient tumors from multiple tissues of origin in a
pan-cancer analysis.12 In prostate tumors, these genes are
often inactivated via complex genomic rearrangements,52
lesions that can be difficult to detect with WES. Thus, the
somatic hypermutation with characteristic indel and sSNV
signaturesmightbeuseful for identifyingMMR-deficient tu-
mors as clinical sequencing becomes more widely adopted.
Biallelic BRCA2 mutations were relatively common in
aggressive and metastatic PCa tumors. Defects in this gene
are a potent driver of mutagenic processes in tumors with
germline or somatic variants, defining a unique molecular
subtype of PCa. BRCA2-deficient PCa tumors do not have
more SVs than other tumors, suggesting that the aggressive
nature of these cancers is not solely due to structural rear-
rangements. Instead, our data suggest that the higher rate
of sSNVs and indels, as well as the increased deleteriousness
of the indels, might contribute substantially to tumor evo-
lution and progression in BRCA2-deficient PCa tumors.The AmOur analysis also highlights the need to evaluate all variant
types for both germline and somatic mutations in BRCA2,
because half of the deficient tumors have somatic-only dis-
ruptions. Finally, our work strongly implicates BRCA2 sta-
tus and the HR-deficiency-associated molecular signature
as potentially important prognostic and treatment selec-
tion biomarkers in aggressive and metastatic PCa.Accession Numbers
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